The Effect of Eighteen-Month Metformin Treatment in Obese Adolescents: Comparison of Results Obtained in Daily Practice with Results from a Clinical Trial
Table 1
Baseline characteristics of patients treated with off label metformin and treated with metformin in a randomized clinical trial.
Daily clinical practice group ()
RCT group ()
value chi2
value Mann-Whitney
Gender
(i) Boys
11 (57.9)
6 (26.1)
0.037
(ii) Girls
8 (42.1)
17 (73.9)
Age (years)
14.3 (11.7–15.7)
13.6 (12.6–15.3)
0.99
Ethnicity
(i) Caucasian
11 (57.9)
23 (100)
NA
(ii) Other
8 (42.1)
0 (0)
Height (cm)
168.3 (161.5–177.2)
162.9 (159.9–168.0)
0.08
Weight (kg)
92.5 (75.2–104.0)
82.2 (75.4–92.7)
0.16
BMI (kg/m2)
31.3 (28.8–33.8)
29.8 (28.1–34.5)
0.66
BMI-SDS
3.23 (3.05–3.64)
3.10 (2.72–3.52)
0.37
BMI-SDS ≥ 3.0
15 (78.9)
13 (56.5)
0.13
Tanner stage
(i) Prepubertal (TS1)
3 (15.8)
3 (13.0)
0.42
(ii) Pubertal (TS2–4)
5 (26.4)
17 (74.0)
(iii) Postpubertal (TS5)
1 (5.6)
3 (13.0)
(iv) Unknown
10 (52.6)
0 (0)
FPG (mmol/l)
5.0 (4.8–5.6)
4.8 (4.7–5.0)
0.015
FPG ≥ 5.6 mmol/l
5 (26.3)
0 (0)
NA
FPI (μU/ml)
31.0 (22.0–41.9)
18.0 (11.0–27.0)
0.005
FPI > 15 μU/ml
17 (89.5)
14 (60.9)
0.036
HOMA-IR
7.74 (4.48–8.96)
4.00 (2.30–6.36)
0.003
HOMA-IR ≥ 3.4
17 (89.5)
10 (43.5)
0.019
HbA1c (mmol/mol)
36 (32–39)
33 (31–34)
0.052
Data are presented as median (interquartile range) or (%). . RCT: randomized clinical trial; BMI ( SDS): body mass index (standard deviation score); FPG: fasted plasma glucose; FPI: fasted plasma insulin; HOMA-IR: homeostasis model assessment for insulin resistance; NA: not applicable.
